Search results for "Dali"

showing 10 items of 1372 documents

I contesti educativi nell’ospedalizzazione pediatrica

2008

CONTESTI EDUCATIVIOSPEDALIZZAZIONE PEDIATRICAPREVENZIONE
researchProduct

Il progetto Kore: la possibilità di essere madri in ospedale

2008

COUNSELING PSICOLOGICO COMPETENZA MATERNA OSPEDALIZZAZIONE PEDIATRICA
researchProduct

Un servizio di counseling per la trasformazione dei costrutti delle mamme dei bambini ospedalizzati

2008

COUNSELING PSICOLOGICOCOMPETENZA MATERNAOSPEDALIZZAZIONE PEDIATRICA
researchProduct

LA CALUNNIA DIFENSIVA AI CONFINI DEL DIRITTO DI DIFESA: SULLA NECESSITÀ DI DISTINGUERE TRA CALUNNIA IMPLICITA E CALUNNIA-MEZZO

2020

La giurisprudenza sembra avere ormai individuato un criterio sufficientemente stabile per decidere quando la calunnia difensiva sia lecita e quando non lo sia: a tal fine, occorrerebbe verificare che tra calunnia e difesa corra (quella che i giudici chiamano) una stretta connessione funzionale; la quale, peraltro, dipenderebbe anche dalle modalità concrete della calunnia: quanto più dettagliata e credibile sia questa, tanto meno stretta sarebbe la sua connessione funzionale con la difesa. Nell’articolo si sostiene che, sebbene le soluzioni giurisprudenziali alle quali si giunge in applicazione di questo criterio appaiano generalmente condivisibili, il criterio stesso ne costituisce una gius…

Calunnia - Diritto di difesa - Stretta connessione funzionale - Modalità concreteSettore IUS/17 - Diritto Penale
researchProduct

Challenges and new prospects in hepatosplenic γδ T-cell lymphoma.

2014

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoid neoplasms characterized by aggressive clinical behavior and dismal prognosis. Hepatosplenic γδ T-cell lymphoma (γδ-HSTL) is a particular form of PTCL that arises from a small subset of γ/δ T-cell receptor-expressing lymphocytes. γδ-HSTL has a rapidly progressive course and poor outcome due also to its refractoriness to conventional chemotherapy regimens. The very low incidence of γδ-HSTL, along with its propensity to mimic different pathological entities, makes this lymphoma a true diagnostic challenge. In this review, we highlight the biological and clinical features of γδ-HSTL that contribute to making this lymphoma…

Cancer ResearchHepatosplenic T-cell lymphomaSpleenDiseaseBiologyT cell lymphomaAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansT-cell lymphomaPathologicalgamma delta T cell lymphomahepatosplenic T cell lymphomaSplenic NeoplasmsLiver NeoplasmsLymphoma T-Cell PeripheralReceptors Antigen T-Cell gamma-deltaHematologymedicine.diseaseCombined Modality Therapyperipheral T cell lymphomasLymphomaT cell lymphoma; gamma delta T cell lymphomas; hepatosplenic T cell lymphoma; peripheral T cell lymphomasTreatment Outcomemedicine.anatomical_structureOncologyImmunologyConventional chemotherapyBone marrowStem Cell Transplantation
researchProduct

Underuse of long-term routine hospital follow-up care in patients with a history of breast cancer?

2011

Abstract Background After primary treatment for breast cancer, patients are recommended to use hospital follow-up care routinely. Long-term data on the utilization of this follow-up care are relatively rare. Methods Information regarding the utilization of routine hospital follow-up care was retrieved from hospital documents of 662 patients treated for breast cancer. Utilization of hospital follow-up care was defined as the use of follow-up care according to the guidelines in that period of time. Determinants of hospital follow up care were evaluated with multivariate analysis by generalized estimating equations (GEE). Results The median follow-up time was 9.0 (0.3-18.1) years. At fifth and…

Cancer ResearchPediatricsMultivariate analysisAftercareComorbidityGUIDELINESGeelaw.inventionCohort StudiesRandomized controlled triallawNetherlandsAged 80 and overSURVIVORSmedicine.diagnostic_testBreast neoplasmFollow-upNeoplasms Second PrimaryMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCombined Modality TherapyUtilizationOncologyPractice Guidelines as TopicRECURRENCESHormonal therapyFemaleGuideline AdherenceHEALTHResearch ArticleCohort studyMammographyAdultmedicine.medical_specialtyOutpatient Clinics HospitalAntineoplastic Agents HormonalMatched-Pair AnalysisBreast Neoplasmslcsh:RC254-282Breast cancerGeneticsmedicineHumansMammographyMETAANALYSISAgedbusiness.industryPatient Acceptance of Health Caremedicine.diseaseComorbidityTRENDSRANDOMIZED-TRIALHealth Care SurveysPhysical therapyPatient ComplianceUPDATESURVEILLANCE MAMMOGRAPHYbusinessFollow-Up Studies
researchProduct

Refining sorafenib therapy: lessons from clinical practice

2015

ABSTRACT  Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symp…

Cancer ResearchSettore SECS-P/06 - Economia ApplicataAntineoplastic AgentAge FactorChild–Pugh Bpostprogression treatmentresponse assessmentdose modificationClinical Trials as TopicLiver Neoplasmsadverse event managementAge FactorsChild-Pugh Bpostprogression treatmenthepatocellular carcinomaGeneral MedicinePrognosisadverse event management; child–Pugh B; dose modification; elderly hepatocellular carcinoma; mRECIST; postprogression treatment; eal-world data; response assessment; sorafenibelderly hepatocellular carcinomaCombined Modality Therapychild–Pugh BClinical PracticeTreatment OutcomeOncologyLiver Neoplasmeal-world dataHepatocellular carcinomaadverse event managementRetreatmentDisease Progressiondose modificationHumanmedicine.drugPhenylurea CompoundNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularDisease ResponsePrognosielderly hepatocellular carcinomaProtein Kinase InhibitorAntineoplastic AgentsmRECISTelderlymRECISTAdverse event management Child–Pugh B dose modification elderly hepatocellular carcinoma mRECIST postprogression treatment real-world data response assessment sorafenibmedicineChild–Pugh BHumansCombined Modality TherapyIntensive care medicineAdverse effectProtein Kinase InhibitorsDose Modificationreal-world databusiness.industryPhenylurea Compoundsmedicine.diseaseDiscontinuationSurgeryreal-world dataresponse assessmentsorafenibbusinessFuture Oncology
researchProduct

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controv…

2016

Contains fulltext : 171468pub.pdf (Publisher’s version ) (Open Access) Primary treatment of rectal cancer was the focus of the second St. Gallen European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Conference. In the context of the conference, a multidisciplinary international expert panel discussed and voted on controversial issues which could not be easily answered using published evidence. Main topics included optimal pretherapeutic imaging, indication and type of neoadjuvant treatment, and the treatment strategies in advanced tumours. Here we report the key recommendations and summarise the related evidence. The treatment strategy for localised rect…

Cancer ResearchStagingColorectal cancermedicine.medical_treatmentNeoplasias Gastrointestinais030230 surgerySYNCHRONOUS LIVER METASTASESImagingCOLORECTAL-CANCER0302 clinical medicineADJUVANT CHEMOTHERAPYTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]SHORT-COURSE RADIOTHERAPYRectal cancerNeoadjuvant therapyGastrointestinal NeoplasmsRectal Neoplasms/drug therapyCombination chemotherapyChemoradiotherapyCombined Modality TherapyTotal mesorectal excisionNeoadjuvant TherapyEuropeNeoplasias do Recto/quimioterapiaOncology030220 oncology & carcinogenesisMEDIAN FOLLOW-UPLife Sciences & BiomedicineDiagnostic Imagingmedicine.medical_specialtyAntineoplastic AgentsLOCAL RECURRENCERisk AssessmentCOURSE PREOPERATIVE RADIOTHERAPY03 medical and health sciencesmedicineHumansGastrointestinal cancerOncology & CarcinogenesisRadiochemotherapyNeoplasm StagingScience & TechnologyRadiotherapyRectal Neoplasmsbusiness.industryGeneral surgeryTOTAL MESORECTAL EXCISIONCancerRANDOMIZED PHASE-IIImedicine.diseaseSurgeryRadiation therapySurgerybusiness1112 Oncology And CarcinogenesisChemoradiotherapyPOSTOPERATIVE CHEMORADIOTHERAPY
researchProduct

Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria

2007

Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are pr…

Cancer Researchmedicine.medical_specialtyMEDLINElymphomaComorbiditySettore MED/08 - Anatomia PatologicaAntiviral AgentsImmunophenotypingDiagnosis DifferentialAntibodies Monoclonal Murine-DerivedBone MarrowAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansCombined Modality TherapySplenic marginal zone lymphomaIntensive care medicineSplenic marginal zone lymphomaNeoplasm StagingChromosome Aberrationsbusiness.industrySplenic NeoplasmsAntibodies MonoclonalDisease ManagementLymphoma B-Cell Marginal ZoneHematologyHepatitis C ChronicPrognosismedicine.diseaseCombined Modality TherapyComorbidityLymphomaSurgeryClinical trialOncologyPractice Guidelines as TopicSplenectomyRituximabDifferential diagnosisRituximabbusinessguidelineSpleenmedicine.drugLeukemia
researchProduct

Bcl-2 and glutathione depletion sensitizes B16 melanoma to combination therapy and eliminates metastatic disease.

2007

Abstract Purpose: Advanced melanoma resists all current therapies, and metastases in the liver are particularly problematic. Prevalent resistance factors include elevated glutathione (GSH) and increased expression of bcl-2 in melanoma cells. GSH has pleiotropic effects promoting cell growth and broad resistance to therapy, whereas Bcl-2 inhibits the activation of apoptosis and contributes to elevation of GSH. This study determined the in vivo efficacy of combination therapies administered while GSH and Bcl-2 were individually and simultaneously decreased in metastatic melanoma lesions. Experimental Design: Highly metastatic murine B16 melanoma (B16M-F10) cells have elevated levels of both G…

Cancer Researchmedicine.medical_specialtySkin NeoplasmsCombination therapyPaclitaxelGlutamineMelanoma ExperimentalBiologyMetastasischemistry.chemical_compoundMiceIn vivoInternal medicinemedicineAnimalsNeoplasm MetastasisAcivicinHematologyTumor Necrosis Factor-alphaMelanomaX-RaysGlutathioneThionucleotidesmedicine.diseaseAntineoplastic Agents PhytogenicCombined Modality TherapyGlutathioneTreatment OutcomeOncologychemistryProto-Oncogene Proteins c-bcl-2ToxicityCancer researchClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct